June 21, 2021
Winship Webinar: Role of Supportive and Palliative Care in Oncology
Supportive and palliative oncology helps patients and their caregivers with the emotional, psychosocial, physical and spiritual aspects of dealing with a cancer diagnosis and treatment. In this Winship Webinar, palliative care specialists Kimberly Curseen, MD and Ali Zarrabi, MD discuss the role of supportive and palliative oncology in a multidisciplinary team setting.
May 20, 2021
Winship Webinar: Updates in CAR T-Cell Therapy for Non-Hodgkin Lymphoma
Immunotherapy is advancing cancer treatment. One treatment in particular, chimeric antigen receptor T-cell (CAR T) therapy, is improving lives for patients with lymphoma. In this live webinar, Winship hematologist Jean Koff, MD, MS, will review updates in the use of CAR T-cell therapy as a promising treatment strategy for patients with certain types of lymphoma.
April 14, 2021
Winship Webinar: Fertility Preservation for Cancer Survivors
For many patients with cancer, particularly patients of child-bearing age, treatment may cause side effects in reproductive organs impacting their ability to have children. In this webinar, Winship oncofertility specialists Akanksha Mehta, MD and Austin Schirmer, MD discuss how cancer treatment may impact a patient's future fertility and shared evidence-based approaches for fertility preservation and treatment.
June 1, 2020
Winship Webinar: Advancing Radiation Oncology in the Era of COVID-19
Winship radiation oncologists Jeffrey Bradley, MD, Kristin Higgins, MD and Bill Stokes, MD discuss updates regarding cancer care and COVID-19. The discussion also included Winship’s expertise in clinical trials and updates for ASTRO and ESTRO head and neck cancer guidelines.
May 29, 2020
Winship Webinar: Winship at ASCO 2020
Winship's Sagar Lonial, MD and Suresh Ramalingam, MD preview Winship clinical research featured at the 2020 ASCO Virtual Scientific Program including the DREAMM-2 study looking at belantamab mafodotin as a new treatment option for patients with refractory/relapsed multiple myeloma, and the CheckMate 227 trial, which led to FDA approval of the immunotherapy combination of nivolumab and ipilimumab for metastatic non-small cell lung cancer.